Published in J Clin Oncol on October 07, 2013
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood (2015) 1.81
Progress in central nervous system lymphomas. Br J Haematol (2014) 0.96
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol (2015) 0.95
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how? Int Ophthalmol Clin (2014) 0.85
Primary CNS lymphoma. Curr Hematol Malig Rep (2014) 0.85
Whither whole brain radiotherapy for primary CNS lymphoma? Neuro Oncol (2014) 0.81
Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol (2014) 0.79
The role of whole brain radiation in primary CNS lymphoma. Blood (2016) 0.78
Neuro-oncology: Primary CNS lymphoma treatment--the devil is in the details. Nat Rev Neurol (2015) 0.78
The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am (2016) 0.77
Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma? Neuro Oncol (2014) 0.77
Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. J Exp Clin Cancer Res (2016) 0.76
Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. Radiat Oncol (2016) 0.75
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget (2016) 0.75
Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol (2016) 0.75
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol (2016) 0.75
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer. Mol Clin Oncol (2017) 0.75
Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience. J Radiat Res (2015) 0.75
New approaches in primary central nervous system lymphoma. Chin Clin Oncol (2015) 0.75
Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment? Neuro Oncol (2015) 0.75
Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee. J Neurooncol (2017) 0.75
Primary CNS Lymphoma. J Clin Oncol (2017) 0.75
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol (2017) 0.75
Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood Res (2017) 0.75
A Regional Multicenter Retrospective Analysis of Patients with Primary Central Nervous System Lymphoma Diagnosed from 2000-2012: Treatment Patterns and Clinical Outcomes. Cureus (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
Glioblastoma and other malignant gliomas: a clinical review. JAMA (2013) 4.99
Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin (2012) 4.77
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin (2006) 3.67
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
How I treat extramedullary acute myeloid leukemia. Blood (2011) 3.42
Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med (2007) 3.39
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Malignant spinal-cord compression. Lancet Oncol (2005) 2.71
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Brain metastases. Neurol Clin (2003) 2.44
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 2.41
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30
A systematic review of the benefits of home telecare for frail elderly people and those with long-term conditions. J Telemed Telecare (2007) 2.28
The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg (2010) 2.26
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood (2004) 2.12
Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer (2006) 2.09
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Neuromuscular complications of cancer diagnosis and treatment. J Support Oncol (2005) 2.06
Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer (2010) 2.06
Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci (2003) 1.99
The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer (2002) 1.98
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Outcome results in macular hole surgery: an evaluation of internal limiting membrane peeling with and without indocyanine green. Ophthalmology (2003) 1.93
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst (2010) 1.91
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res (2005) 1.86
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer (2004) 1.81
Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma (2003) 1.77
Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med (2003) 1.76
Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiat Oncol Biol Phys (2011) 1.76
Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology (2011) 1.74
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol (2006) 1.74
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle Nerve (2008) 1.66
Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck (2006) 1.65
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol (2008) 1.65
Craniofacial and intracranial manifestations of langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol (2008) 1.64
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Intracranial dural metastases. Cancer (2009) 1.59
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Advancing the treatment of malignant glioma: act local, think global. Cancer Invest (2004) 1.59
Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys (2008) 1.58
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58